By purchasing this product, the buyer acknowledges and agrees that: The product will be handled only by qualified professionals or licensed research institutions
Sport-specific movements come last, only after strength and flexibility have been adequately restored
Component In 1 vail: ascorbic acid 100mg, biotin 60ug, cyanocobalamin 5ug, dexpanthenol 15mg, ergocalciferol 200IU, folic acid 400ug, nicotinamide 40mg, Pyridoxine Hydrochloride 4.86mg Riboflavin Sodium Phosphate 3.6mg, Thiamine Hydrochloride 3.81mg, Tocopherol Acetate 10mg, retinol 3300IU Identification: Freeze-dried injection in a brown vial containing a yellow powder Efficacy / Effect: 1
Free specialist consultation Benefits Separate from GLP-1 mechanism synergy when combined with Ozempic/Mounjaro 22.7% weight loss in CagriSema (REDEFINE-1, 68 weeks) best result among incretin therapies 10.8% in monotherapy over 26 weeks (Phase 2, Lancet 2021) In T2D on metformin: 15.6% weight, 2.2% HbA1c combined with semaglutide Does NOT cause hypoglycemia (unlike insulin and sulfonylureas) Gradual 16-week titration smooth buildup, minimal side effects Convenient weekly dosing half-life ~7 days Cardiovascular risk reduction in T2D (secondary endpoint REDEFINE-2) Alternative/addition for patients plateauing on GLP-1 monotherapy Who it's for Weight plateau on GLP-1 (Ozempic/Mounjaro) adding cagrilintide gives +610% reduction Patients who don't tolerate high GLP-1 doses lower dose + cagrilintide instead of dose increase T2D on metformin better glycemic and weight control than semaglutide-mono Biohackers / advanced users seeking maximum CagriSema protocol effect Post-surgical weight maintenance (bariatric) adjuvant against recidivism Those wanting SEPARATE appetite control mechanism without duplicating GLP-1 How to take Standard 16-week titration (Novo Nordisk Phase 3 CagriSema): Weeks 14: 0.25 mg subcutaneous once weekly
